CareersInvestor RelationsPress Room
Login
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases & Conditions
  4. Simplify Cardiometabolic Testing
Cardiometabolic key visual US

Simplify Cardiometabolic TestingIs your laboratory ready for the increasing demand in cardiometabolic testing?

Interconnected cardiovascular, liver, and renal conditions are on the rise.1

The heart, liver, and kidneys are deeply interrelated, often sending subtle, early signals of distress long before advanced disease becomes clinically apparent

Help clinicians and patients see the full picture of cardiometabolic health: 

  • Utilize the first and only prognostic high‑sensitivity troponin I assay available in the U.S. to help predict future cardiac event risk in symptomatic patients
  • Measure 3 markers of direct liver fibrosis to provide a non‑invasive assessment of disease progression and outcomes with the only commercially authorized prognostic blood test, the Enhanced Liver Fibrosis (ELF) test
  • Help detect heart failure earlier, before symptoms escalate with NT-proBNP II and BNP
  • Enable confident reporting with <5% interference from common HbA1c variants (HbC, HbD, HbE, HbS, and HbA2)
  • Support diabetes management with additional assays including insulin, fructosamine, C-Peptide and additional chemistry testing
Lab professional 
Doctor sitting next to patient

Is your laboratory prepared for the increasing demand in cardiometabolic testing? ​

Cardiometabolic conditions do not develop in isolation. The heart, liver, and kidney often send silent, interconnected signals of distress, long before advanced cardiometabolic disease presents.2 The right assays can help clinicians connect risk signals earlier—before overt disease progression takes place.

Cardiometabolic disease is increasing in the U.S., with the American Heart Association projecting that by 2050 obesity will affect 60.6% of adults, diabetes 26.8%, and overall cardiovascular disease more than 6 in 10 U.S. adults (over 184 million people).8  Metabolic-associated liver disease is expected to affect 41% of the US population (122 million) by 2050.

As cardiometabolic conditions continue to rise, laboratories are uniquely positioned to influence care earlier—before disease progression limits treatment options. Siemens Healthineers assays can help laboratories respond to these demands with consistency, reliability, and clinical confidence.

Lab tech in front of an Atellica Solution

Support strategic cardiometabolic assessment—without added complexity

We understand the operational realities of the modern laboratory. Increased pressure for faster turnaround times, and staffing reductions make it challenging to stay ahead of clinical and operational demands. Our cardiometabolic assays are designed to fit seamlessly into your existing workflows while elevating clinical value.

Operational simplicity enables broader, more consistent cardiometabolic assessment—without adding workflow burden to already strained laboratories.

Consolidating your cardiometabolic assay menu on a single system like Siemens Healthineers Atellica Solution enables your lab to:

  • Support earlier accurate risk stratification
  • Standardize use of a single analyzer across cardiovascular, kidney, diabetes and liver testing
  • Support clinicians navigating complex, multi‑organ disease
5
Siemens Healthineers. Enhanced Liver Fibrosis (ELF) Instructions for Use. October 2022.
6
Siemens Healthineers Atellica IM High-Sensitivity Troponin IFU 11200498, Rev. 10, 2024-09
7
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine. 2002;347:161–167.
*
National Glycohemoglobin Standardization Program 
**
International Federation of Clinical Chemistry and Laboratory Medicine
Subscription Button Icon

Subscribe to news from Siemens Healthineers USA

Be the first to know about our events, training, and news